179 related articles for article (PubMed ID: 33549984)
1. EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
Hung A; Lee KM; Alba PR; Li Y; Gao AZ; Hintze BJ; Efimova OV; Shenolikar R; Pavilack M; Simmons D; Kelley MJ; Lynch JA; Reed SD
Cancer Treat Res Commun; 2021; 27():100327. PubMed ID: 33549984
[TBL] [Abstract][Full Text] [Related]
2. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
Enewold L; Thomas A
PLoS One; 2016; 11(6):e0156728. PubMed ID: 27294665
[TBL] [Abstract][Full Text] [Related]
3. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
4. EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
Larson KL; Huang B; Chen Q; Tucker T; Schuh M; Arnold SM; Kolesar JM
PLoS One; 2020; 15(8):e0237790. PubMed ID: 32810185
[TBL] [Abstract][Full Text] [Related]
5. EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.
Helland Å; Andersen KK; Myklebust TÅ; Johannesen TB; Aarøe J; Enerly E
Cancer Treat Res Commun; 2022; 33():100636. PubMed ID: 36155129
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.
Lynch JA; Berse B; Chun D; Rivera D; Filipski KK; Kulich S; Viernes B; DuVall SL; Kelley MJ
Clin Lung Cancer; 2017 Jul; 18(4):401-409. PubMed ID: 28038980
[TBL] [Abstract][Full Text] [Related]
7. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
[TBL] [Abstract][Full Text] [Related]
8. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Desai S; Kim C; Veytsman I
Curr Oncol Rep; 2019 Aug; 21(9):84. PubMed ID: 31410582
[TBL] [Abstract][Full Text] [Related]
9.
Palacio S; Pontes L; Prado E; Arshad J; Ali R; Piha T; Bacchi CE; Mudad R; Lopes G
Oncologist; 2019 Apr; 24(4):e137-e141. PubMed ID: 30446583
[TBL] [Abstract][Full Text] [Related]
10. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kehl KL; Hassett MJ; Schrag D
Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
[TBL] [Abstract][Full Text] [Related]
11. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
12. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
14. Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns.
Peters M; Kim ES; Hirsch V
J Glob Oncol; 2019 Feb; 5():1-7. PubMed ID: 30811306
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
[TBL] [Abstract][Full Text] [Related]
17. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y
Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation testing practice in advanced non-small cell lung cancer.
Bar J; Cyjon A; Flex D; Sorotsky H; Biran H; Dudnik J; Peylan-Ramu N; Peled N; Nechushtan H; Gips M; Katsnelson R; Rosenberg SK; Merimsky O; Onn A; Gottfried M
Lung; 2014 Oct; 192(5):759-63. PubMed ID: 24964874
[TBL] [Abstract][Full Text] [Related]
19. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
